Mabion SA

Mabion S.A. is a Polish biopharmaceutical CDMO providing extensive drug development and biomanufacturing services to pharmaceutical and Biotech companies globally. We offer services for clinical and commercial manufacture of recombinant protein therapeutics, including process and analytical development services, GMP manufacture of Drug Substance (from small scale up to 4 x 2.000 liter single-use bioreactor sizes), GMP manufacture of Drug Product in our state-of-the-art filling line and an extensive set of analytics and QC tests. This is supported by a robust quality assurance and regulatory affairs department. In addition to our regular CDMO offering, Mabion also took part in the global fight against the coronavirus pandemic by signing a record contract with Novavax Inc. in October 2021 for the commercial production of the antigen for their COVID-19 vaccine. This partnership has proven to be very successful, leading to several subsequent additional services offered by Mabion, augmenting the main commercial-scale manufacturing contract. We aim to establish ourselves as a key global player in the global contract manufacturing and contract drug development market offering a broad range of high-quality integrated services to the Biotech and pharmaceutical market. Mabion is a public Company, listed on the Warsaw Stock Exchange (WSE: MAB).